Searched for
CRDMO COMPANIES
“Reallocate, Diversify, Reposition”: Ajay Srivastava flags rising macro risks for investorsIndian markets face rising macro risks from global shocks, currency pressure, and energy prices, impacting domestic consumption and corpora...- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Stick to defensive and quality themes amid volatile global setup: Mayuresh JoshiIndian stock markets are showing a strong rebound. Investors are now carefully selecting companies with good earnings and strong finances. ...
- Anthem BioSciences shares jump 4% as Citi initiates with Buy rating. Check target, upside potentialShares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...
- Biocon shares in focus as company swings to Rs 84 crore profit in Q2Biocon reported a strong turnaround in Q2FY26 with a net profit of Rs 84.5 crore against a loss of Rs 16 crore last year, driven by 21% YoY...
- Jefferies' pharma bets are Divi's Laboratories and 3 smallcaps, with up to 30% upside. Here's whyJefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Scienc...
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Avendus Fund, SBI Life lead funding in AragenAvendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...
- Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the ...
- Anthem Biosciences' Rs 3,395 crore IPO opens for subscription. Should you bid?Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band...
- Is Anthem Biosciences IPO a risky bet for investors?Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit h...
- Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...
- India's contract drug makers seek government support in China fightIndia's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With ...
- India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...
- Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and SyngeneMacquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressure...
- Investing in 2025: ICICIDirect's Pankaj Pandey betting on 4 big themes this yearWe are constructive on markets and believe the recent correction offers a good entry point to start accumulation for long term wealth gener...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....
- Sai Life Science grew fast, but pricing looks expensiveThe issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...
- Jubilant Pharmova's US arm prepays Rs 626 crore term loanJubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore ...
Load More
